Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer

Objective: This study evaluated the cost-effectiveness of nivolumab plus ipilimumab vs. chemotherapy in the first-line setting for patients with advanced non-small-cell lung cancer (NSCLC) from the US payer perspective. Materials and methods: A Markov model wasdeveloped to evaluate the cost and effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Wan, Xiaomin, Zeng, Xiaohui, Peng, Liubao, Peng, Ye, Liu, Qiao, Yi, Lidan, Luo, Xia, Deng, Qijian, Tan, Chongqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430394/
https://www.ncbi.nlm.nih.gov/pubmed/34512315
http://dx.doi.org/10.3389/fphar.2021.580459

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430394/
https://www.ncbi.nlm.nih.gov/pubmed/34512315
http://dx.doi.org/10.3389/fphar.2021.580459

Ejemplares similares